A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Figure 7
Dose-dependent PCSK9 mRNA response in mice after a single i.v. injection at 5–40 mg/kg.
(A) Dose-response curve of PCSK9 mRNA levels in the liver (mean and SEM, n = 5), where the ED50 estimation is 9 mg/kg and maximum effect 95% reduction of the PCSK9 mRNA. (B) There is no change in mRNA levels of LDLR or Apobec. (C) LDLR protein is up-regulated 2–3 fold in the treated animals in the high dose groups. (Mean and SEM, n = 4–5).